RUBICON2026-01-012026-03-31RUBICON2026-03-31RUBICON2026-01-012026-03-31CompositionOfBoardOfDirectors1RUBICON2026-03-31CompositionOfBoardOfDirectors1RUBICON2026-01-012026-03-31CompositionOfBoardOfDirectors2RUBICON2026-03-31CompositionOfBoardOfDirectors2RUBICON2026-01-012026-03-31CompositionOfBoardOfDirectors3RUBICON2026-03-31CompositionOfBoardOfDirectors3RUBICON2026-01-012026-03-31CompositionOfBoardOfDirectors4RUBICON2026-03-31CompositionOfBoardOfDirectors4RUBICON2026-01-012026-03-31CompositionOfBoardOfDirectors5RUBICON2026-03-31CompositionOfBoardOfDirectors5RUBICON2026-01-012026-03-31CompositionOfBoardOfDirectors6RUBICON2026-03-31CompositionOfBoardOfDirectors6RUBICON2026-01-012026-03-31CompositionOfBoardOfDirectors7RUBICON2026-03-31CompositionOfBoardOfDirectors7RUBICON2026-01-012026-03-31CompositionOfBoardOfDirectors8RUBICON2026-03-31CompositionOfBoardOfDirectors8RUBICON2026-01-012026-03-31CompositionOfBoardOfDirectors9RUBICON2026-03-31CompositionOfBoardOfDirectors9RUBICON2026-01-012026-03-31CompositionOfCommittees14RUBICON2026-03-31CompositionOfCommittees14RUBICON2026-01-012026-03-31CompositionOfCommittees15RUBICON2026-03-31CompositionOfCommittees15RUBICON2026-01-012026-03-31CompositionOfCommittees16RUBICON2026-03-31CompositionOfCommittees16RUBICON2026-01-012026-03-31CompositionOfCommittees41RUBICON2026-03-31CompositionOfCommittees41RUBICON2026-01-012026-03-31CompositionOfCommittees42RUBICON2026-03-31CompositionOfCommittees42RUBICON2026-01-012026-03-31CompositionOfCommittees43RUBICON2026-03-31CompositionOfCommittees43RUBICON2026-01-012026-03-31CompositionOfCommittees68RUBICON2026-03-31CompositionOfCommittees68RUBICON2026-01-012026-03-31CompositionOfCommittees69RUBICON2026-03-31CompositionOfCommittees69RUBICON2026-01-012026-03-31CompositionOfCommittees70RUBICON2026-03-31CompositionOfCommittees70RUBICON2026-01-012026-03-31CompositionOfCommittees71RUBICON2026-03-31CompositionOfCommittees71RUBICON2026-01-012026-03-31CompositionOfCommittees95RUBICON2026-03-31CompositionOfCommittees95RUBICON2026-01-012026-03-31CompositionOfCommittees96RUBICON2026-03-31CompositionOfCommittees96RUBICON2026-01-012026-03-31CompositionOfCommittees97RUBICON2026-03-31CompositionOfCommittees97RUBICON2026-01-012026-03-31CompositionOfCommittees122RUBICON2026-03-31CompositionOfCommittees122RUBICON2026-01-012026-03-31CompositionOfCommittees123RUBICON2026-03-31CompositionOfCommittees123RUBICON2026-01-012026-03-31CompositionOfCommittees124RUBICON2026-03-31CompositionOfCommittees124RUBICON2026-01-012026-03-31CompositionOfCommittees125RUBICON2026-03-31CompositionOfCommittees125RUBICON2026-03-31MeetingOfBoardOfDirectors1RUBICON2026-01-012026-03-31MeetingOfBoardOfDirectors1RUBICON2026-03-31MeetingOfBoardOfDirectors2RUBICON2026-01-012026-03-31MeetingOfBoardOfDirectors2RUBICON2026-03-31MeetingOfBoardOfDirectors3RUBICON2026-01-012026-03-31MeetingOfBoardOfDirectors3RUBICON2026-03-31MeetingOfBoardOfDirectors4RUBICON2026-01-012026-03-31MeetingOfBoardOfDirectors4RUBICON2026-01-012026-03-31MeetingOfCommittees1RUBICON2026-03-31MeetingOfCommittees1RUBICON2026-01-012026-03-31MeetingOfCommittees2RUBICON2026-03-31MeetingOfCommittees2RUBICON2026-01-012026-03-31MeetingOfCommittees3RUBICON2026-03-31MeetingOfCommittees3RUBICON2026-01-012026-03-31MeetingOfCommittees4RUBICON2026-03-31MeetingOfCommittees4RUBICON2026-01-012026-03-31MeetingOfCommittees5RUBICON2026-03-31MeetingOfCommittees5RUBICON2026-01-012026-03-31MeetingOfCommittees6RUBICON2026-03-31MeetingOfCommittees6RUBICON2026-01-012026-03-31MeetingOfCommittees7RUBICON2026-03-31MeetingOfCommittees7RUBICON2026-01-012026-03-31MeetingOfCommittees8RUBICON2026-03-31MeetingOfCommittees8RUBICON2026-01-012026-03-31MeetingOfCommittees9RUBICON2026-03-31MeetingOfCommittees9RUBICON2026-01-012026-03-31MeetingOfCommittees10RUBICON2026-03-31MeetingOfCommittees10RUBICON2026-01-012026-03-31MeetingOfCommittees11RUBICON2026-03-31MeetingOfCommittees11RUBICON2025-12-31RUBICON2026-03-31UnlistedCompanyDomain1RUBICON2026-01-012026-03-31UnlistedCompanyDomain1RUBICON2025-12-31UnlistedCompanyDomain1RUBICON2026-03-31ImpositionOfFineOrPenaltyDomain1RUBICON2026-03-31ImpositionOfFineOrPenaltyDomain2RUBICON2026-03-31ImpositionOfFineOrPenaltyDomain3RUBICON2026-03-31ImpositionOfFineOrPenaltyDomain4RUBICON2026-03-31OngoingTaxLitigationsOrDisputesDomain1RUBICON2026-03-31OngoingTaxLitigationsOrDisputesDomain2RUBICON2026-03-31OngoingTaxLitigationsOrDisputesDomain3RUBICON2026-03-31OngoingTaxLitigationsOrDisputesDomain4RUBICON2026-03-31OngoingTaxLitigationsOrDisputesDomain5RUBICON2026-03-31OngoingTaxLitigationsOrDisputesDomain6RUBICON2026-03-31OngoingTaxLitigationsOrDisputesDomain7RUBICON2026-03-31OngoingTaxLitigationsOrDisputesDomain8xbrli:pure544578RUBICONNOTLISTEDINE506V01022RUBICON RESEARCH LIMITED2025-04-012026-03-31Yearly2026-03-31EquitytruetruetruetruetruefalseNothing to Report.trueAny othertruecomr07665OriginaltruefalseMrsPratibha Sudhir Pilgoankar******00401516Executive DirectorNot ApplicableMD1954-06-12falseActiveNA2000-06-011000MrParag Suganchand Sancheti******07686819Executive DirectorNot ApplicableCEO1983-10-16falseActiveNA2017-01-271010MrVarun Talukdar******08312687Non-Executive - Non Independent DirectorNot Applicable1984-05-18falseActiveNA2023-09-051000MrShantanu Rastogi******06732021Non-Executive - Non Independent DirectorNot Applicable1979-03-26falseActiveNA2019-04-033020MrAnand Agarwal******06481297Non-Executive - Non Independent DirectorNot Applicable1976-05-12falseInactiveNA2025-01-032026-02-031000OthersMrChangavalli Venkat******02391159Non-Executive - Independent DirectorChairperson1953-09-25falseActiveNA2024-06-112024-06-1121.211110MrKumarapuram Gopalakrishnan Ananthakrishnan******00019325Non-Executive - Independent DirectorNot Applicable1957-02-10falseActiveNA2024-06-112024-06-1121.213342MrMilind Anil Patil******02546815Non-Executive - Independent DirectorNot Applicable1963-11-01falseActiveNA2024-07-112024-07-1120.212221MsPRADNYA NANDKUMAR SARAVADE******08472973Non-Executive - Independent DirectorNot Applicable1964-06-18falseActiveNA2026-02-032026-02-031.291120truetruetruetruetrueAudit Committee02546815Milind Anil PatilNon-Executive - Independent DirectorChairperson2024-07-24Audit Committee02391159Changavalli VenkatNon-Executive - Independent DirectorMember2024-07-24Audit Committee06732021Shantanu RastogiNon-Executive - Non Independent DirectorMember2024-07-24Nomination and remuneration committee00019325Kumarapuram Gopalakrishnan AnanthakrishnanNon-Executive - Independent DirectorChairperson2024-07-24Mr. Kumarapuram Gopalakrishnan Ananthakrishnan was re-designated from Member to Chairperson with effect from October 13, 2025.Nomination and remuneration committee06732021Shantanu RastogiNon-Executive - Non Independent DirectorMember2024-07-24Nomination and remuneration committee02391159Changavalli VenkatNon-Executive - Independent DirectorMember2024-07-24Mr. Venkat Changavalli was re-designated from Chairperson to Member with effect from October 13, 2025.Stakeholders Relationship Committee00019325Kumarapuram Gopalakrishnan AnanthakrishnanNon-Executive - Independent DirectorChairperson2024-07-24Stakeholders Relationship Committee06732021Shantanu RastogiNon-Executive - Non Independent DirectorMember2024-07-24Stakeholders Relationship Committee07686819Parag Sugnachand SanchetiExecutive DirectorMember2024-07-24Stakeholders Relationship Committee08472973PRADNYA NANDKUMAR SARAVADENon-Executive - Independent DirectorMember2026-02-03Risk Management Committee07686819Parag Suganchand SanchetiExecutive DirectorChairperson2024-07-24Risk Management Committee02546815Milind Anil PatilNon-Executive - Independent DirectorMember2024-07-24Risk Management Committee08312687Varun TalukdarNon-Executive - Non Independent DirectorMember2024-07-24Corporate Social Responsibility Committee00401516Pratibha Sudhir PilgoankarExecutive DirectorChairperson2014-12-27Corporate Social Responsibility Committee07686819Parag Suganchand SanchetiExecutive DirectorMember2017-02-21Corporate Social Responsibility Committee02391159Changavalli VenkatNon-Executive - Independent DirectorMember2024-07-24Corporate Social Responsibility Committee08472973PRADNYA NANDKUMAR SARAVADENon-Executive - Independent DirectorMember2026-02-032025-12-16true8832026-02-0348true8832026-03-1236true8632026-03-3118true873Audit Committee2025-11-13true3320Audit Committee2026-02-0381true3320Audit Committee2026-03-3054true3220Nomination and remuneration committee2025-10-29true3320Nomination and remuneration committee2026-02-0396true3320Nomination and remuneration committee2026-03-3054true3220Corporate Social Responsibility Committee2025-11-13true3310Corporate Social Responsibility Committee2026-03-18124true4420Corporate Social Responsibility Committee2026-03-3112true4420Risk Management Committee2026-03-31true3310Stakeholders Relationship Committee2026-03-30true4320truetruetruetrueYestruetruetrueMs. Deepashree TanksaleCompany Secretary and Compliance OfficerYeshttps://www.rubicon.co.in/know-usYeshttps://www.rubicon.co.in/pdf/MOA%20%20AOA.pdfYeshttps://www.rubicon.co.in/pdf/Directors%20Brief%20Profile%20(1).pdfYeshttps://www.rubicon.co.in/pdf/Draft%20Letter%20of%20Appointment-Independent%20Director.pdfYeshttps://www.rubicon.co.in/pdf/Rubicon%20Committee%20Constitution.pdfYeshttps://www.rubicon.co.in/pdf/Code%20of%20Conduct_Directors%20and%20Sr%20Management.pdfYeshttps://www.rubicon.co.in/pdf/Whistle%20Blower%20and%20Vigil%20Mechanism%20Policy.pdfYeshttps://www.rubicon.co.in/investors#Yeshttps://www.rubicon.co.in/pdf/Related-Party-Transactions-Policy.pdfYeshttps://www.rubicon.co.in/pdf/Policy-on-Material-Subsidiaries.pdfYeshttps://www.rubicon.co.in/pdf/Policy%20for%20familiarisation%20programmes%20for%20independent%20directors.pdfYeshttp://rubicon.co.in/investors#Yeshttps://www.rubicon.co.in/investors#Yeshttps://www.rubicon.co.in/reports-filingsYeshttps://www.rubicon.co.in/disclosures/SHP_Rubicon_31122025.pdfNAYeswww.rubicon.co.in/pdf/corporate-announcement/Announcement%20under%20Regulation%2030%20(LODR)%20Analyst%20%20Investor%20Meet%20-%20Intimation.pdfYeshttps://www.rubicon.co.in/recordings/10039745.mp3NAYeshttps://www.rubicon.co.in/pdf/corporate-announcement/Rubicon_Newspaper%20Advertisement_05.02.2026.pdfYeshttps://www.rubicon.co.in/pdf/Credit%20Raitng%20-%202025.pdfYeshttps://www.rubicon.co.in/reports-filingsNAYeshttps://www.rubicon.co.in/pdf/Policy%20for%20Determining%20Materiality%20of%20Events%20or%20Information%20for%20Disclosure.pdfYeshttps://www.rubicon.co.in/pdf/Contact%20details%20of%20Key%20Managerial%20Personnel%20for%20determining%20Materiality.pdfYeshttps://www.rubicon.co.in/investors#NAYeshttps://www.rubicon.co.in/pdf/Dividend%20distribution%20Policy.pdfYeshttps://www.rubicon.co.in/pdf/Annual%20Return%20FY%202024.pdfYeshttps://www.rubicon.co.in/pdf/Employee%20Benefit%20Scheme%20.pdfYeshttps://www.rubicon.co.in/investors#Yeshttps://www.rubicon.co.in/investors#YesYesYesYesYesYesYesYesYesYesYesYesYesYesYesYesYesYesYesYesYesYesYesYesNANANANAYesYesYesNAYesYesYesNAYesYesYesYesYesYesNAYesYesYesYesNAMs. Deepashree TanksaleCompany Secretary and Compliance OfficerYesMs. Deepashree TanksaleCompany Secretary and Compliance OfficerfalseMs. Deepashree TanksaleCompany Secretary and Compliance OfficerThane2026-04-2805500Radiance MH Sunrise Eleven Private Limited2026-03-2700.0690.069Reserve Bank of India (Foreign Exchange Department)Compounding Order passed under Section 15 of FEMA, 1999 for regularization of contravention. The matter was disposed upon payment of compounding amount.2026-01-06Delay in filing Form ESOP beyond prescribed timeline (30 days) under FEMA 20(R) Regulations, 2017 relating to issuance of ESOPs to a non-resident employee289000Indian Customs (Air Cargo Complex, Sahar, Mumbai)Final assessment of Bill of Entry with levy of fine2026-01-02Procedural / assessment-related matter (no offence or penalty)5000Indian Customs (Air Cargo Complex, Sahar, Mumbai)Final assessment of Bill of Entry with levy of fine2026-01-03Procedural / assessment-related matter (no offence or penalty)6000Indian Customs (Air Cargo Complex, Sahar, Mumbai)Final assessment of Bill of Entry with levy of fine2026-02-18Procedural / assessment-related matter (no offence or penalty)10000Office of the assessment unit of Income Tax Department2022-09-26Status as on 31 December 2025: Submissions were filed and the matter is awaiting for disposal. No final adverse order has been passed as on 31-12-2025. Brief: Company received an assessment order dated September 26, 2022 (“AO Order”) from the office of the assessment unit of Income Tax Department under section143(3) read with section 144 B of the Income Tax Act, 1961 for an outstanding demand of ₹ 55.51 million imposed by assessing officer for the A.Y. 2020-21. The order was passed for inter alia disallowance u/s 14A and 37 of Income Tax Act, 1961 of the expense claimed on account of the difference between issue price and face value of shares issued pursuant to the ESOP Scheme of ₹ 79.41 million. The Company has filed an appeal dated October 21, 2022 with Hon’ble Commissioner of Income-Tax (Appeals). The matter is currently pending.All further information requested during the quarter was provided. As on 31-03-2026 , the matter is pending adjudication before the Commissioner of Income-tax (Appeals) / NFAC .Office of the assessment unit of Income Tax Department2023-07-26Last disclosure: Matter is awaiting adjudication; no final order received as on 31-12-2025. Brief: Company received an assessment order dated July 26, 2023 (“AO Order”) from the office of the assessment unit of Income Tax Department under section143(3) read with section 144 B of the Income Tax Act, 1961 for CASS scrutiny on the return of income filed. The total additional income tax demand raised as per AO Order is ₹ 407.36 million. Company filed an appeal dated April 19, 2024 with Hon’ble Commissioner of Income-Tax (Appeals), in relation to the demand for additional income tax raised. The matter is currently pending.The Hon’ble CIT(A) / NFAC, vide order dated 28.03.2026 passed under section 250 of the Income-tax Act, 1961, allowed the appeal. The demand of Rs. 393.6 million arising on account of ICDS adjustment has been fully deleted, and the major issues has been adjudicated in favour of the Assessee. At present, only a minor issue remains, pertaining to interest on late payment of TDS amounting to Rs. 1,710.Intimation order u/s 143(1) of the Income Tax Act, 19612023-12-29Last Disclosure: Matter pending with the Income-tax Department as on 31-12-2025. No final rectification / disposal as on 31-12-2025. Brief: Company received an intimation order u/s 143(1) of the Income Tax Act, 1961 dated December 12, 2023 for an outstanding amount payable of ₹ 81.42 million. On December 29, 2023, our Company paid ₹ 75.24 million out of the outstanding amount payable determined by the intimation order dated December 12, 2023. Further, our Company intimated by way of a letter dated March 28, 2024 to Assessing Offer of the Income Tax Department about the foreign tax benefit claim (“Claim”) for A.Y. 2021-2022 and 2022-2023 on inter-corporate loan extended to wholly owned subsidiary in USA and had filed the belated form 67 for A.Y. 2021-2022 and 2022-2023 and claimed credit for the interest income on the said loan in income tax return filed for A.Y. 2023-24. The Company is awaiting a reply and the matter is currently pending.The Company will contesting the matter in appeal before the appropriate appellate authority against the draft assesssment order received during the quarter under Section 144C(1) of the Income-tax Act, 1961, with an addition of Rs. 206.8 million has been proposed on account of adjustment in the Arm’s Length Price (ALP) as suggested by the Transfer Pricing Office.Edenbridge Pharmaceuticals LLC2025-03-13Last Disclosure: ngoing. The matter is currently pending. Brief: Plaintiff withdrew it's Motion for Preliminary Injunction on 26-09-2025. Brief: Edenbridge Pharmaceuticals LLC filed a complaint against the Company and Advagen Pharma Ltd (Material Subsidiary) before before the Court of Chancery for the State of Delaware, for: (i) breach of contract; (ii) misappropriation of trade secrets; and (iii) unjust enrichment. The Company and its Material Subsidiary has denied breach of the said confidentiality agreement.(Refer Prospectus for detailed proceedings)This matter was voluntarily dismissed by Edenbridge on 10-03-2026.Pfizer INC. and Pfizer Ireland Pharmaceuticals2024-05-23Last Disclosure: Ongoing. The matter is currently pending. Brief:Pfizer INC. and Pfizer Ireland Pharmaceuticals filed a complaint against the Company before United States District Court for the District of Delaware, for patent infringement under patent laws of the United States of America arising from Company’s submission for abbreviated new drug application no. 219440 to the US FDA. (Refer Prospectus for detailed proceedings)Status as on March 31, 2026: Ongoing. The matter is currently pending.Pierre Fabre Medicament SAS; Université De Bordeaux; Centre Hospitalier Universitaire De Bordeaux; and Pierre Fabre Pharmaceuticals, Inc., (“Plaintiffs”)2024-07-12Last Disclosure: Ongoing. The matter is currently pending. Brief:Plaintiffs filed a complaint against the Company before United States District Court for the District of Delware for patent infringement under patent laws of the United States of America arising from Plaintiff’s submission for abbreviated new drug application (ANDA) no. 219574 to the US FDA (Refer Prospectus for detailed proceedings)Status as on March 31, 2026: Closed. This matter was settled and case closed during the reporting quarter.Metacel Pharmaceuticals LLC (Counterclaim filed by Rubicon Research Limited2023-08-08Last Disclosure:Rubicon Counterclaim: Ongoing. The matter is currently in the discovery phase. The Metacel Patent Infringement Action - Metacel Pharmaceuticals LLC initiated a Complaint against Rubicon Research [Private] Limited on 29 October 2021. Rubicon won its Summary Judgment Motion, with a Final Judgment entered on 31 August 2023, the Court finding that “Rubicon’s ANDA Product that is the subject of ANDA No. 214445 (the “Rubicon ANDA”) does not infringe any claim of the ’502 patent.” Rubicon successfully defended its Judgment before the U.S. Court of Appeals for the Federal Circuit and returned the action to U.S. District Court (see e.g. Dkt. Nos. 164 and 170.) The Rubicon Antitrust Counterclaim - Defendant, Rubicon Research [Private] Limited’s First Amended Answer, Affirmative Defenses and Counterclaim was filed on 8 August 2023, thereby initiating suit against Counterclaim Defendant, Metacel. The Counterclaim action would be stayed, by virtue of Metacel’s Appeal of the Trial Court’s Final Judgment of Non-Infringement, to the U.S. Court of Appeals for the Federal Circuit. Following entry of the Fed. Cir. Opinion affirming the Trial Court’s Decision on 23 April 2025, Rubicon sought and received an Order lifting the case stay (Dkt. No. 168) and has continued to pursue its antitrust counterclaim against Metacel through 31 December 2025.Status as on March 31, 2026: Ongoing. The matter is currently pending.Office of Deputy Commissioner of Income Tax, Mumbai2026-01-05Not ApplicableAdvaGen Pharma Ltd, USA, a material step down subsidiary company, received a demand notice under section 156 of the Income-Tax Act, 1961 from the office of Deputy Commissioner of Income Tax, Mumbai. The notice specifies the total demand payable including tax and interest of INR 4,18,84,613/- for assessment year 2021-22. This arises from the denial of a DTAA exemption on income of INR 10,03,57,800, following the tax authority’s conclusion that the 'Make Available' clause under the India-US DTAA was applicable. Assessment year 2021-22. On 19/01/26, an Appeal has been filed before the Income Tax Appellate Tribunal (ITAT), against the assessment order passed under Section 143(3) read with Section 144C(13) of the Income-tax Act, 1961. As on 31-03-2026, the matter is currently pending.